Gillette Buys Future $1B HQ Site in South Boston
The razor manufacturer’s parent, Procter & Gamble, paid $99.3 million to acquire the 232 A St. property from Breakthrough Properties.
The razor manufacturer’s parent, Procter & Gamble, paid $99.3 million to acquire the 232 A St. property from Breakthrough Properties.
Gillette’s headquarters will relocate to a planned office and R&D building next to its longtime South Boston campus, freeing up space for a major redevelopment.
A vision to turn West Cambridge into a second Kendall Square is coming apart amid record lab vacancies across the region, as the fundamentals of development look set to shift back in favor of multifamily housing.
A life science development will contribute $6.5 million toward the design and construction of a flood berm designed to protect portions of Boston’s Seaport District from sea level rise.
The developer of a proposed 335,000-square-foot office-lab building in Boston’s Seaport District plans to cantilever the far west side of the building because a portion of the Interstate 90 tunnel runs beneath the 232 A St. site.
Construction of the initial 900,000-square-foot phase of Harvard’s Enterprise Research Campus in Allston is beginning this week after developers received a $750-million construction loan led by Otera Capital.
A life science developer that’s acquired properties in Boston and Cambridge raised $3 billion for pay for its 4.6 million-square-foot pipeline of projects.
With average asking rents for lab space nearing triple digits, life science developers have won bidding wars for recent sites hitting the market in Boston’s Seaport District.
A life science developer that’s partnering on Harvard University’s next Allston project is adding an East Cambridge office property to its real estate portfolio.
The field of Greater Boston lab developers is widening. So who are they? What are their strategies? And who have they hired to execute their plans?
A Cambridge biopharma company that’s working on treatments for type 1 diabetes and cancer will occupy a speculative new life science development in South Boston.